Gujarat Themis Biosyn Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 382.7 as of 05 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd is 0 as of March 2021 .The P/E Ratio of Novelix Pharmaceuticals Ltd is 0 as of March 2021 . The Market Cap of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of March 2021 .The Market Cap of Novelix Pharmaceuticals Ltd is ₹ 5.48 crore as of March 2021 . The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The revenue of Novelix Pharmaceuticals Ltd for the Dec '25 is ₹ 48.4 crore as compare to the Sep '25 revenue of ₹ 36.39 crore. This represent the growth of 33% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The ebitda of Novelix Pharmaceuticals Ltd for the Dec '25 is ₹ 1.31 crore as compare to the Sep '25 ebitda of ₹ 0.73 crore. This represent the growth of 79.45% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 13.24 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -3.41% The net profit of Novelix Pharmaceuticals Ltd changed from ₹ -0.35 crore to ₹ 1 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Novelix Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Novelix Pharmaceuticals Ltd

Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company.
Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016. Initially, the company was engaged in finance and investments in securities.
They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.
Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Novelix Pharmaceuticals Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Novelix Pharmaceuticals Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,170 Cr while Market cap of Novelix Pharmaceuticals Ltd is 58 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Novelix Pharmaceuticals Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Novelix Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Novelix Pharmaceuticals Ltd?

As of May 5, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹382.7. On the other hand, Novelix Pharmaceuticals Ltd stock price is INR ₹40.5.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Novelix Pharmaceuticals Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Novelix Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.